SBIR/STTR Research Award

Non Invasive Tear Fluid Glucose Sensor Photonic Crystals

Award identifier 7077fe501c062f5cd135cc16224626299a716fb4654c90f7d1b09d1219570406Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$98,960

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GLUCOSE SENSING TECHNOLOGIES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): This Phase I research and development program will develop novel, real-time, noninvasive (or minimally invasive) glucose colorimetric sensors for tear fluid. These sensors are based on new photonic crystal chemical sensing materials recently invented at the University of Pittsburgh. These photonic crystal sensors use arrays of nanosclae particles to diffract visible light. The wavelength of light diffracted and the color perceived visually can be used to determine the glucose concentration. This glucose sensing material will be utilized as the sensing element of a contact lens, as well as an ocular insert designed for use underneath the lower eyelid. The patients will determine their glucose concentration by utilizing the simple spectrometer device. The observed diffraction wavelength reports on the patient's tear fluid glucose concentration. Since the tear fluid glucose concentration tracks the blood glucose concentration, a tear fluid glucose measurement determines the blood glucose concentration. We will optimize the responsivity of these sensor materials and develop fabrication methods to incorporate the sensing material in contact lenses and ocular insert-type devices which will be tested in Phase II of this program in animals and humans. These minimally invasive tear fluid glucose sensors will revolutionize glycemic control for patients with diabetes mellitus. These devices will permit painless, continuous, inexpensive monitoring of glucose levels, which will dramatically increase patient glucose monitoring compliance and the long term health consequences of diabetes mellitus.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.